[{"id":"03e89ab8-dacb-455b-84eb-7a4c304f5cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06338657","created_at":"2024-03-29T14:40:53.948Z","updated_at":"2024-07-02T16:35:02.933Z","phase":"Phase 1","brief_title":"FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer","source_id_and_acronym":"NCT06338657","lead_sponsor":"University of Southern California","biomarkers":" PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nanoencapsulated paclitaxel (FID-007)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-17"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"006e2786-ec9f-435c-b1a8-55c1b4f1678e","acronym":"PROTEOM","url":"https://clinicaltrials.gov/study/NCT04183569","created_at":"2021-01-18T20:23:47.835Z","updated_at":"2024-07-02T16:36:45.526Z","phase":"","brief_title":"Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04183569 - PROTEOM","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1","pipe":" | ","alterations":" CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation","tags":["BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 32","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-04-29"}]